Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease
Information source: Nycomed
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Gastroesophageal Reflux Disease
Intervention: Pantoprazole (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Nycomed Official(s) and/or principal investigator(s):
Thomas Bethke, MD, MBA, Study Director, Affiliation: Nycomed Deutschland GmbH, 78467 Konstanz, Germany
Overall contact:
Nycomed Info, Email: info@nycomed.com
Summary
The aim of this study is to quantify the characteristics of gastrointestinal symptoms and
their alterations during treatment with pantoprazole in a large patient population with
gastroesophageal reflux disease (GERD). The study will provide further data on safety and
tolerability of pantoprazole.
Clinical Details
Official title: Pantoprazole 20/40 mg in Reflux-Associated Complaints With Focus on Gastrointestinal Symptoms
Study design: Case-Only, Prospective
Primary outcome: Progression of reflux-associated gastrointestinal symptoms
Secondary outcome: Analysis of treatment success according to different clinical subgroups (reflux symptoms, functional dyspepsia (FD-symptoms), Irritable Bowel Syndrom (IBS symptoms))
Eligibility
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Main inclusion criteria:
- Patients with gastroesophageal reflux disease (GERD)
Main exclusion criteria:
- Criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter
4. 3)
Locations and Contacts
Nycomed Info, Email: info@nycomed.com
Nycomed Deutschland GmbH, Hamburg 20123, Germany; Recruiting
Additional Information
Starting date: January 2009
Ending date: June 2009
Last updated: January 26, 2009
|
